Karen Chu
Directeur Général chez Harvest Integrated Research Organization
Profil
Karen Chu is the founder of Harvest Integrated Research Organization.
She is currently a Director at Acesion Pharma ApS and Cellestia Biotech AG.
Previously, she worked as a Corporate Vice President-Asia Pacific at PAREXEL International Corp.
Postes actifs de Karen Chu
| Sociétés | Poste | Début |
|---|---|---|
Acesion Pharma ApS
 Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Directeur/Membre du Conseil | - |
Cellestia Biotech AG
 Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland. | Directeur/Membre du Conseil | - |
Harvest Integrated Research Organization
 Harvest Integrated Research Organization Miscellaneous Commercial ServicesCommercial Services Harvest Integrated Research Organization (HIRO) is a clinical research organization that provides cross-border solutions and services to its clients, including pre-clinical strategic planning, clinical trial design, regulatory, pharmacovigilance, statistics, data management, project management, and clinical and medical monitoring services. The private company is based in Shanghai, CN, and has subsidiaries in the United States. HIRO aims to become a market-leading, integrated clinical research organization that collaborates with biotech and pharmaceutical companies to bring new products to the market, providing more effective solutions for patients worldwide. The Chinese company was founded in 2020 by Karen Chu, who has been the CEO since then. | Directeur Général | - |
Anciens postes connus de Karen Chu
| Sociétés | Poste | Fin |
|---|---|---|
| PAREXEL INTERNATIONAL CORPORATION | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
PAREXEL International Corp.
 PAREXEL International Corp. Miscellaneous Commercial ServicesCommercial Services PAREXEL International Corp. provides biopharmaceutical services. It offers clinical research and logistics, medical communications, consulting, commercialization and advanced technology products and services for pharmaceutical, biotechnology and medical device industries. The company was founded in 1983 and is headquartered in Newton, MA. | Commercial Services |
Acesion Pharma ApS
Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Health Technology |
Cellestia Biotech AG
Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland. | Health Technology |
Harvest Integrated Research Organization
Harvest Integrated Research Organization Miscellaneous Commercial ServicesCommercial Services Harvest Integrated Research Organization (HIRO) is a clinical research organization that provides cross-border solutions and services to its clients, including pre-clinical strategic planning, clinical trial design, regulatory, pharmacovigilance, statistics, data management, project management, and clinical and medical monitoring services. The private company is based in Shanghai, CN, and has subsidiaries in the United States. HIRO aims to become a market-leading, integrated clinical research organization that collaborates with biotech and pharmaceutical companies to bring new products to the market, providing more effective solutions for patients worldwide. The Chinese company was founded in 2020 by Karen Chu, who has been the CEO since then. | Commercial Services |
